[HTML][HTML] Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial

…, DA Norris, R Crean, DL Graham, E Huang, E Ratti… - Nature medicine, 2023 - nature.com
Tau plays a key role in Alzheimer’s disease (AD) pathophysiology, and accumulating
evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT …

[HTML][HTML] Comparison of medical and consumer wireless EEG systems for use in clinical trials

E Ratti, S Waninger, C Berka, G Ruffini… - Frontiers in human …, 2017 - frontiersin.org
Objectives: To compare quantitative EEG signal and test-retest reliability of medical grade and
consumer EEG systems. Methods: Resting state EEG was acquired by two medical grade (…

Defining SOD1 ALS natural history to guide therapeutic clinical trial design

…, J Liu, T Siddique, LH Wang, TD Bird, E Ratti… - Journal of Neurology …, 2017 - jnnp.bmj.com
Importance Understanding the natural history of familial amyotrophic lateral sclerosis (ALS)
caused by SOD1 mutations (ALS SOD1 ) will provide key information for optimising clinical …

Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS-FTD brain, propagate neuronal loss

…, L Cao, AC Gomez, K Evans, E Ratti… - Science translational …, 2021 - science.org
Triggers of innate immune signaling in the CNS of patients with amyotrophic lateral sclerosis
and frontotemporal degeneration (ALS/FTD) remain elusive. We report the presence of …

[HTML][HTML] Ultra high-field (7tesla) magnetic resonance spectroscopy in Amyotrophic Lateral Sclerosis

…, B Keil, R Lawson, P Cernasov, E Ratti… - PLoS …, 2017 - journals.plos.org
The main objective of this study was to utilize high field (7T) in vivo proton magnetic
resonance imaging to increase the ability to detect metabolite changes in people with ALS, …

[HTML][HTML] TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer's disease

M Shulman, J Kong, J O'Gorman, E Ratti… - Nature Aging, 2023 - nature.com
In Alzheimer’s disease, the spread of aberrantly phosphorylated tau is an important criterion
in the Braak staging of disease severity and correlates with disease symptomatology. Here, …

[HTML][HTML] Presynaptic AMPA receptors in health and disease

L Zanetti, M Regoni, E Ratti, F Valtorta, J Sassone - Cells, 2021 - mdpi.com
AMPA receptors (AMPARs) are ionotropic glutamate receptors that play a major role in
excitatory neurotransmission. AMPARs are located at both presynaptic and postsynaptic plasma …

[HTML][HTML] Longitudinal cognitive decline in patients with mild cognitive impairment or dementia due to Alzheimer's disease

…, J Kong, P Maruff, J Jaeger, E Huang, E Ratti - The Journal of Prevention …, 2022 - Springer
Sensitive cognitive assessments accurately detect and track cognitive decline in Alzheimer’s
disease. The Cogstate battery was used to measure cognitive change in cognitively normal …

Regional prefrontal cortical atrophy predicts specific cognitive-behavioral symptoms in ALS-FTD

E Ratti, K Domoto-Reilly, C Caso, A Murphy… - Brain imaging and …, 2021 - Springer
Amyotrophic Lateral Sclerosis-Frontotemporal Dementia (ALS-FTD) may present typical
behavioral variant FTD symptoms. This study aims to determine whether profile and severity of …

[HTML][HTML] Preclinical rodent toxicity studies for long term use of ceftriaxone

E Ratti, JD Berry, DJ Greenblatt, L Loci, AS Ellrodt… - Toxicology reports, 2015 - Elsevier
A 6-months rodent toxicology and pharmacokinetic (PK) study was performed to provide
supportive safety data for long-term use of intravenous ceftriaxone in a clinical trial in patients …